Serological Responses in Patients with Severe Acute Respiratory Syndrome Coronavirus Infection and Cross-Reactivity with Human Coronaviruses 229E, OC43, and NL63
Open Access
- 1 November 2005
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 12 (11) , 1317-1321
- https://doi.org/10.1128/cdli.12.11.1317-1321.2005
Abstract
The serological response profile of severe acute respiratory syndrome (SARS) coronavirus (CoV) infection was defined by neutralization tests and subclass-specific immunofluorescent (IF) tests using serial sera from 20 patients. SARS CoV total immunoglobulin (Ig) (IgG, IgA, and IgM [IgGAM]) was the first antibody to be detectable. There was no difference in time to seroconversion between the patients who survived (n = 14) and those who died (n = 6). Although SARS CoV IgM was still detectable by IF tests with 8 of 11 patients at 7 months postinfection, the geometric mean titers dropped from 282 at 1 month postinfection to 19 at 7 months (P = 0.001). In contrast, neutralizing antibody and SARS CoV IgGAM and IgG antibody titers remained stable over this period. The SARS CoV antibody response was sometimes associated with an increase in preexisting IF IgG antibody titers for human coronaviruses OC43, 229E, and NL63. There was no change in IF IgG titer for virus capsid antigen from the herpesvirus that was used as an unrelated control, Epstein-Barr virus. In contrast, patients who had OC43 infections, and probably also 229E infections, without prior exposure to SARS CoV had increases of antibodies specific for the infecting virus but not for SARS CoV. There is a need for awareness of cross-reactive antibody responses between coronaviruses when interpreting IF serology.Keywords
This publication has 23 references indexed in Scilit:
- Antigenic Cross‐Reactivity between Severe Acute Respiratory Syndrome–Associated Coronavirus and Human Coronaviruses 229E and OC43The Journal of Infectious Diseases, 2005
- Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with PneumoniaJournal of Virology, 2005
- False-Positive Results in a Recombinant Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV) Nucleocapsid Enzyme-Linked Immunosorbent Assay Due to HCoV-OC43 and HCoV-229E Rectified by Western Blotting with Recombinant SARS-CoV Spike PolypeptideJournal of Clinical Microbiology, 2004
- Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patientsJournal of Clinical Virology, 2004
- Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus InfectionThe Journal of Infectious Diseases, 2004
- Identification of a new human coronavirusNature Medicine, 2004
- Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 LineagePublished by Elsevier ,2003
- Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory SyndromeNew England Journal of Medicine, 2003
- Epstein–Barr virus (EBV) infection in infancyJournal of Clinical Virology, 2001
- Coronavirus Infection in Acute Lower Respiratory Tract Disease of InfantsThe Journal of Infectious Diseases, 1974